top of page
The Professional Network for Healthcare Experts
FDA approves Orzeyful as first treatment to address the full range of narcolepsy type 1 symptoms
The orexin receptor agonist provides adults with a treatment that targets the underlying loss of orexin signalling rather than managing individual symptoms separately.
nuaxia
Aug 72 min read
NexTel Medical signs letter of intent to acquire Xycota Biosciences and expand into neuroplasticity therapeutics
The proposed acquisition would add Xycota’s preclinical CNS pipeline and exosome-based delivery platform to NexTel Medical, including lead programme XYCO-01 for frontotemporal dementia.
nuaxia
Aug 72 min read
FDA approves Orzeyful as first treatment to address the full range of narcolepsy type 1 symptoms
The orexin receptor agonist provides adults with a treatment that targets the underlying loss of orexin signalling rather than managing individual symptoms separately.
nuaxia
Aug 62 min read
Supernus and Indivior agree merger to create $2.2 billion CNS biopharmaceutical company
The all-stock transaction combines complementary central nervous system portfolios spanning neuroscience and addiction medicine, creating a larger commercial-stage company with a broader product portfolio and pipeline.
nuaxia
Aug 62 min read
Medscape Neurology Compensation Report 2026
The Medscape Neurologist Compensation Report 2026 shows US neurologist earnings continuing on a familiar trajectory:
nuaxia
Jun 235 min read
bottom of page